sodium oxybate extended-release
Adjunctive therapy • Brands: Lumryz
Last reviewed: 2025-12-30
General information
- Class: Adjunctive therapy
- Common US brands: Lumryz
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-12-30
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Nighttime CNS depressant (sodium oxybate; oxybate/GHB) once-nightly extended-release oral suspension indicated for cataplexy or excessive daytime sleepiness in narcolepsy (patients 7+); Schedule III with boxed warning for respiratory depression and abuse/misuse and dispensed under a REMS. Alcohol is contraindicated due to dose-dumping risk (label).
Metabolism & Half‑life
- Metabolism: Non-CYP metabolism (GHB metabolic pathways) (label).
- Half‑life: Single-dose range 0.5–1 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- LUMRYZ (sodium oxybate) for extended-release oral suspension prescribing information — DailyMed (2025)
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline — Journal of Clinical Sleep Medicine (2021)
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment — Journal of Clinical Sleep Medicine (2021)
- Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy — Sleep (2021)